Litigation Details for ZS Pharma, Inc. v. Macleods Pharmaceuticals Ltd. (D. Del. 2023)

ZS Pharma, Inc. v. Macleods Pharmaceuticals Ltd. (D. Del. 2023)

Docket		Date Filed	2023-10-20
Court	District Court, D. Delaware	Date Terminated	2025-05-08
Cause	35:271 Patent Infringement	Assigned To	Jennifer L. Hall
Jury Demand	None	Referred To
Patents	11,738,044
Link to Docket	External link to docket

Details for ZS Pharma, Inc. v. Macleods Pharmaceuticals Ltd. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-10-20				External link to document

ZS Pharma v. Macleods Pharmaceuticals: Litigation Summary, Patent Claims, and Generic Entry Risk

Last updated: August 15, 2026

ZS Pharma’s patent case against Macleods Pharmaceuticals concerns a proposed generic version of Lokelma, the potassium-binding drug sodium zirconium cyclosilicate. ZS Pharma filed the action in the U.S. District Court for the District of Delaware after receiving a Paragraph IV certification challenging Lokelma patents listed in the FDA’s Orange Book. The case is a Hatch-Waxman action under 21 U.S.C. § 355(j)(5)(B)(iii), with the central commercial issue being whether Macleods can launch before the asserted Lokelma patents expire.

What is ZS Pharma, Inc. v. Macleods Pharmaceuticals Ltd.?

Item	Detail
Case	ZS Pharma, Inc. v. Macleods Pharmaceuticals Ltd.
Civil action	No. 1:23-cv-01190
Court	U.S. District Court for the District of Delaware
Plaintiff	ZS Pharma, Inc., an AstraZeneca company
Defendants	Macleods Pharmaceuticals Ltd. and affiliated Macleods entities
Product	Lokelma, sodium zirconium cyclosilicate
Regulatory pathway	Abbreviated New Drug Application, or ANDA
Legal framework	Hatch-Waxman patent litigation
Filing basis	Paragraph IV patent certification
Primary commercial issue	Whether Macleods can market generic sodium zirconium cyclosilicate before the relevant patent barriers expire

The complaint alleges that Macleods’ ANDA product would infringe patents covering Lokelma’s zirconium silicate composition, pharmaceutical formulation, and therapeutic use. The case was one of several Lokelma-related patent actions filed by ZS Pharma against prospective generic applicants in the same general period. (ZS Pharma, Inc. v. Macleods Pharmaceuticals Ltd., 2023)

What drug and formulation are protected in the Macleods case?

Lokelma contains sodium zirconium cyclosilicate, a nonabsorbed inorganic cation exchanger used to treat hyperkalemia. The FDA-approved product is supplied as a powder for oral suspension in strengths of 5 grams and 10 grams. The product exchanges potassium in the gastrointestinal tract and reduces serum potassium levels. (U.S. Food and Drug Administration [FDA], 2018)

The litigation is commercially important because a generic applicant may not need to copy every commercial attribute of Lokelma. In an ANDA case, infringement can arise from the proposed generic label, the composition described in the ANDA, or the reasonably foreseeable use of the product for patented indications.

What formulations are protected by Lokelma patents?

The Lokelma patent estate has included claims directed to:

• Zirconium silicate compositions;
• Particle size and physical characteristics;
• Pharmaceutical compositions containing sodium zirconium cyclosilicate;
• Oral suspension formulations;
• Dosing regimens for reducing or maintaining serum potassium;
• Treatment of hyperkalemia;
• Manufacturing and preparation methods.

The exact scope depends on the claims asserted against Macleods and the ANDA formulation disclosed to ZS Pharma. Composition claims generally create the highest entry risk because a noninfringing generic substitute is difficult to develop where the active ingredient itself is claimed. Method-of-use claims can be narrower if the generic label omits the patented indication or limits dosing instructions.

Which patents protect Lokelma in the Orange Book?

The relevant patent estate includes patents associated with zirconium silicate compositions and their medical use. Public Orange Book records and the complaint should be read together because the Orange Book identifies listed patents, while the complaint identifies the claims ZS Pharma selected for litigation.

Patent category	Commercial subject matter	Generic-entry significance
Composition patents	Sodium zirconium cyclosilicate and related zirconium silicate materials	High, if the ANDA product practices the claimed composition
Formulation patents	Oral powder and suspension characteristics	Moderate to high, depending on claim breadth
Method-of-use patents	Treatment or control of hyperkalemia	Variable; label wording is critical
Manufacturing patents	Preparation or processing of zirconium silicate	Usually dependent on the ANDA manufacturing process

The principal Lokelma patent family has included U.S. Patent Nos. 8,802,152 and 9,561,197, along with later-issued patents and continuation applications relating to zirconium silicate compositions and use. Patent-by-patent infringement analysis requires comparison with the patent numbers and claims identified in the complaint and the operative pleadings. (U.S. Patent and Trademark Office [USPTO], n.d.; FDA, n.d.)

When does Lokelma lose exclusivity?

Lokelma’s FDA approval date was May 18, 2018. The product’s five-year new chemical entity exclusivity period therefore expired in May 2023, subject to the precise FDA exclusivity record. That expiration allowed ANDA applicants to submit applications earlier if they could certify to the listed patents.

The relevant patent expiration dates extend beyond regulatory exclusivity. A simplified exclusivity timeline is:

Event	Date or period
FDA approval of Lokelma	May 18, 2018
Five-year NCE exclusivity	Expired in 2023
Early generic filing window	Open after the applicable exclusivity restrictions and based on patent certifications
ZS Pharma litigation against Macleods	2023
Generic launch	Potentially delayed by the Hatch-Waxman stay, patent judgment, settlement, or later patent expiration

Patent expiration cannot be determined from the FDA’s five-year exclusivity date. The operative date depends on the specific patents asserted, any patent-term adjustment or extension, pediatric exclusivity, terminal disclaimers, and the outcome of litigation.

What was Macleods’ Paragraph IV challenge?

Macleods’ ANDA certification reportedly challenged listed Lokelma patents under Paragraph IV. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

ZS Pharma’s filing of the Delaware action triggered the statutory 30-month stay of FDA approval under the Hatch-Waxman Act, assuming the action was timely filed after receipt of the Paragraph IV notice. The stay prevents FDA approval of the ANDA during the statutory period unless a court judgment or other statutory event terminates the stay earlier. (21 U.S.C. § 355(j)(5)(B)(iii))

What does the 30-month stay mean for Macleods?

The stay delays FDA approval, not necessarily commercial development. Macleods may continue preparing its product, manufacturing supply, and launch strategy. It generally cannot commercially launch an FDA-approved generic until:

1. The asserted patents are held invalid, unenforceable, or not infringed;
2. The stay expires before final resolution;
3. ZS Pharma and Macleods reach a settlement permitting entry;
4. The asserted patent barriers expire; or
5. Another statutory or judicial event removes the approval block.

The stay is separate from the ultimate patent merits. A stay expiration does not itself establish that Macleods has the right to launch without infringement risk.

What patent litigation affects Lokelma generic entry?

The Macleods case is part of a broader set of Lokelma ANDA disputes involving prospective generic manufacturers. The existence of multiple defendants increases the likelihood of coordinated claim-construction issues, overlapping invalidity theories, and potentially different settlement dates.

The core legal issues are likely to include:

• Claim construction for zirconium silicate composition terms;
• Whether the ANDA product meets claimed composition or particle characteristics;
• Anticipation and obviousness;
• Written description and enablement;
• Patent-term and terminal-disclaimer issues;
• Whether the proposed label induces infringement of method-of-use claims;
• Whether any asserted patent is unenforceable because of inequitable conduct or other equitable defenses.

No merits ruling should be inferred from the filing of the complaint. The complaint reflects ZS Pharma’s infringement position, while Macleods’ answer, invalidity contentions, claim-construction positions, and expert reports determine the substantive defense record. (ZS Pharma, Inc. v. Macleods Pharmaceuticals Ltd., 2023)

How strong is the Lokelma patent estate against Macleods?

The estate appears strongest where ZS Pharma can establish that Macleods’ ANDA product necessarily practices a composition claim. A composition claim can block entry even if the generic applicant changes packaging, manufacturing location, or nonactive excipients.

Formulation claims are more fact-dependent. Macleods may contest infringement by arguing that its particle size, suspension properties, excipients, or processing conditions fall outside the asserted claim limitations.

Method-of-use claims present a separate risk profile. Under the induced-infringement framework, the proposed generic label and expected physician use are central. A label that includes treatment instructions covered by a patent can create substantial exposure. A skinny-label strategy may reduce that exposure, but it is effective only if the omitted use is genuinely carved out and the remaining label does not encourage the patented use.

Patent-strength assessment

Patent type	Strength against a conventional ANDA	Main defense
Active composition	High	Noninfringement, invalidity, or a materially different active ingredient
Formulation	Moderate to high	Different excipients, particle characteristics, or dosage form
Treatment method	Moderate	Label carve-out and no induced infringement
Manufacturing process	Variable	Nonuse of the claimed process

The commercial strength of the estate therefore depends less on the number of patents than on whether at least one broad, unexpired composition or formulation claim survives.

What is the Orange Book status of Lokelma?

The FDA Orange Book is the principal public source for patents listed against approved drug products. Listed patents can include patents covering active ingredients, formulations, compositions, and methods of use. The Orange Book does not determine infringement or validity. Those issues are decided in federal court.

For Lokelma, the relevant Orange Book analysis should distinguish:

• Patents listed against the specific approved product;
• Patents asserted in the Macleods complaint;
• Patents that remain unexpired;
• Patents subject to terminal disclaimers;
• Patents with expiration dates affected by patent-term adjustment or extension.

A listed patent can create an ANDA certification obligation even if its ultimate enforceability is disputed. Conversely, a patent not listed in the Orange Book may still create ordinary patent-infringement risk, although it may not support the same statutory ANDA stay.

Has ZS Pharma settled with Macleods?

The public litigation record should be checked for a dismissal order, settlement-related filing, or stipulated judgment before treating the case as resolved. A Hatch-Waxman settlement may include:

• A licensed generic entry date;
• A launch date tied to patent litigation outcomes;
• A royalty or supply arrangement;
• Restrictions on authorized generic competition;
• A covenant not to sue;
• A no-challenge provision, subject to antitrust and regulatory limits.

A dismissal alone does not disclose the commercial terms of a settlement. Hatch-Waxman settlements are often filed under confidentiality protections, with the parties submitting a redacted agreement or a certification to the Federal Trade Commission and Department of Justice under the Medicare Prescription Drug, Improvement, and Modernization Act.

Which companies are challenging Lokelma exclusivity?

The 2023 Lokelma litigation wave involved multiple ANDA applicants, indicating that generic competition was not limited to Macleods. The competitive risk is greater when several applicants challenge the same patent estate because a ruling against one defendant can influence the strategies of others.

The principal competitive variables are:

• Whether the first filer qualifies for 180-day generic exclusivity;
• Whether multiple applicants share the same Paragraph IV timing;
• Whether a settlement grants staggered entry;
• Whether authorized generic supply changes the economics of launch;
• Whether ZS Pharma obtains favorable claim construction across cases.

FDA approval of one ANDA does not automatically resolve every separate defendant’s case. Each applicant’s formulation, manufacturing process, label, and certification record can differ.

What generic launch scenarios exist for Lokelma?

Scenario 1: ZS Pharma wins on infringement and validity

Macleods remains blocked until the relevant patents expire or a later license permits entry. This is the most favorable outcome for ZS Pharma and preserves branded-market share for the remaining patent term.

Scenario 2: Macleods wins on noninfringement

FDA approval may proceed after the court enters an appropriate judgment or the statutory stay ends. Entry could occur before the nominal expiration of some Lokelma patents.

Scenario 3: Macleods invalidates a key composition patent

Invalidation can materially weaken the estate beyond the individual case, particularly if the patent is asserted against multiple ANDA applicants. Continuation patents may still preserve narrower barriers.

Scenario 4: Settlement establishes a licensed entry date

This is a common commercial resolution in pharmaceutical patent disputes. The entry date may be earlier than patent expiration but later than immediate approval. The economic impact depends on whether the settlement permits an authorized generic and whether other defendants retain independent launch rights.

Scenario 5: Skinny-label entry

Macleods may seek approval for nonpatented uses while omitting patented indications. The strategy reduces method-of-use exposure but does not avoid composition or formulation patents practiced by the product.

What is the revenue exposure from Macleods’ generic?

Lokelma revenue exposure depends on U.S. sales, gross-to-net deductions, payer access, generic pricing, and the number of entrants. A single generic entrant can reduce net pricing before materially displacing volume. Multiple entrants usually accelerate price erosion.

The principal financial variables are:

Variable	Effect on ZS Pharma/AstraZeneca
Early licensed entry	Reduces branded price and volume before patent expiration
Single generic launch	Moderate initial erosion
Multiple generic launches	Faster price compression
Authorized generic	Can defend volume but may reduce branded revenue
Narrow label	Limits generic substitution to approved nonpatented uses
Composition-patent victory	Preserves broader revenue protection

Because Lokelma is a chronic-use product, prescription retention, formulary placement, and adherence will affect the speed of substitution. The case is therefore relevant to both patent timing and the durability of branded net sales.

Key Takeaways

• ZS Pharma v. Macleods is a Delaware Hatch-Waxman case involving a Paragraph IV challenge to patents associated with Lokelma.
• The product is sodium zirconium cyclosilicate, an oral potassium binder for hyperkalemia.
• Lokelma’s five-year NCE exclusivity expired in 2023, but patent protection extends beyond regulatory exclusivity.
• Composition patents present the greatest generic-entry risk if Macleods’ ANDA product necessarily practices the claimed zirconium silicate material.
• Formulation and method-of-use claims create more fact-specific infringement issues.
• The 30-month statutory stay delays FDA approval but does not determine the final patent outcome.
• A settlement, invalidity judgment, noninfringement judgment, or patent expiration could permit Macleods entry.
• The commercial impact depends on the number of generic entrants, any first-filer exclusivity, and the settlement terms.

FAQs About the Lokelma Macleods Patent Case

Is Macleods seeking approval for generic Lokelma?

Yes. The case arises from Macleods’ ANDA for a proposed generic version of sodium zirconium cyclosilicate, marketed by AstraZeneca as Lokelma.

Does the lawsuit mean FDA has approved the Macleods product?

No. A patent lawsuit does not establish FDA approval. FDA approval remains subject to the ANDA review, statutory patent stay, and applicable exclusivity provisions.

Can Macleods launch Lokelma before all listed patents expire?

Potentially. Launch could follow a judgment of noninfringement or invalidity, expiration of the statutory stay, or a settlement granting an earlier license. Launch before patent expiration would carry litigation and damages risk if an asserted patent remains enforceable.

Are Lokelma biosimilars relevant to this case?

No. Lokelma is a small-molecule drug product, not a biologic. The relevant competitive pathway is an ANDA for a generic drug, not a biosimilar application under the Public Health Service Act.

Does a Lokelma patent settlement automatically resolve other generic cases?

No. Each ANDA applicant has a separate application, certification, formulation, and litigation record. A settlement with Macleods may influence other cases but does not automatically terminate them.

References

Food and Drug Administration. (2018). Lokelma prescribing information. U.S. Department of Health and Human Services.

Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. U.S. Department of Health and Human Services.

U.S. Code. (2023). 21 U.S.C. § 355(j): Abbreviated applications for new drugs.

U.S. Patent and Trademark Office. (n.d.). Patent Center and patent assignment records. U.S. Department of Commerce.

ZS Pharma, Inc. v. Macleods Pharmaceuticals Ltd., No. 1:23-cv-01190 (D. Del. filed 2023).